NeuroSense (NRSN) news
Recent news
NeuroSense unveils accelerated, capital-efficient strategy to advance Primec toward potential approval in ALS
NeuroSense Therapeutics has announced a strategic shift aimed at accelerating the development of its lead candidate, Primec, for the treatment of amyotrophic lateral sclerosis (ALS), while optimizing capital efficiency. The company is currently in discussions with Health Canada to define a clear…
AInvest Wire · 5h agoNeuroSense Therapeutics - expects to file submission to Health Canada in coming months
AInvest Wire · Jul 22, 2026NeuroSense Therapeutics rose 48.3% premarket, as the company will report new data from randomized, placebo-controlled, doubled-blind segment of phase 2b PARADIGM ALS trial on Dec.5
NeuroSense Therapeutics rose 48.3% premarket, as the company will report new data from randomized, placebo-controlled, doubled-blind segment of phase 2b PARADIGM ALS trial on Dec.5 More Info: NeuroSense Therapeutics, a company focusing on developing treatments for neurodegenerative diseases,…
AInvest Wire · Dec 5, 2023NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
AInvest Wire · Nov 13, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.